Get started
MODERNA INCMODERNA INCMODERNA INC

MODERNA INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MRNA trade ideas

Are you afraid to buy now ?Read latest news here , here and here . From a high of 180, it tumbles down to 102.68 without any good reasons. My conjecture is the big boys are shaking out the weak buyers, collecting the first pot of gold and short it down hard before accumulating again. And imo, I think the timing is now (I could be wrong) , thus I am taking a nibble first. So, if you have 10,000 to invest, you can divide them into tranches of 50%, 25% and 25%. The ratio is malleable and you can adjust it to your risk tolerance.
NASDAQ:MRNALong
by dchua1969
5
Time is comeThe paper started an uptrend after falling at the close of the Gap. Indicators are well unloaded. Target is -300,350. Upside: 35%. ❤️ If you find this helpful and want more FREE forecasts in TradingView . . . . . Please show your support back, . . . . . . . . Hit the 👍 LIKE button, . . . . . . . . . . . Drop some feedback below in the comment! ❤️ Your Support is very much 🙏 appreciated!❤️ 💎 Want us to help you become a better Stock trader?
NASDAQ:MRNALong
by QuantumLabSignals
2
Big Pharma Holds the LineLast week ended with sell-offs amid fears about the new extremely contagious COVID 19 Omicron variant. Crude and stock markets suffered. But during this brief rally some shares continued to gain, and it is no wonder that these are the stocks of vaccine producers. Pfizer stocks posted a new all-time high on Friday rising by 6.11% to $54.94. Stocks were additionally supported when the company promised to develop a tailor-made vaccine in 100 days if the Omicron variant cannot be tamed by the current vaccine. The shares also reacted to the news that the European Medicines Agency approved the BioNTech-Pfizer vaccine for children aged 5-11. That is good news for the world’s top-selling medicine of the year. In order for the shares to continue on this upside climb, the price of Pfizer stocks need to remain above $50.49, which is the shares’ peak which was reached in August, and also keep with its upward trend that started on November 4 and has a support level at $51.50-51.80. BioNTech stocks also performed well, adding some 14.19% on Friday. The technical picture suggests stocks may rise further as they managed to break through the downward channel they have been on since August 10. Besides, we may see a reverse pattern “double dip” with a neck level crossing $304.35. The implementation of this pattern may boost stock prices to $378.67-401.19. Stock prices are close to the 61.8% Fibonacci correction level of the lows of August-November at $365.13. In case this landmark is passed, investors will have more reasons to push the stock to this year’s highs. Moderna stocks also enjoyed the sunny side of the COVID-19 panic as they soared by 20.57% to $329.63 on Friday, breaking from their downward channel which began on September 23. The next price target is at the $387-395 area, where the 61.8% Fibonacci level from the downside correction of August-November, and the resistance line of the downward trend from August 10 are located. I have already said that all Big Pharma stocks should be included in portfolios as they may all rally. Nevertheless, at the beginning of the new week fears around the South African Omicron variant have faded as the virologist Barry Schoub, who advises the South African government, said he did not believe the variant will lead to a major new wave of serious illness and the vaccine will still protect most people from severe cases of COVID-19. But the overall picture now that there is a new variant in circulation is unclear, and the market may become agitated. In this case the best option is to have downside-resistant stocks in your portfolio. Some people may find profit anywhere!
NASDAQ:MRNALong
by scavoanastasiia
Moderna about to reclaim bullish Channel. Short-Term-BULLISH! Not financial advice! With the new corona variant spreading fear all over the world, PFE and MRNA are running. I think it's possible for MRNA to reclaim the bullish channel, aka the Bull-Trap that broke down, when PFE announced the Paxlovid-med. I got in MRNA way to late, now taking a risky trade, since MRNA gaps like crazy, and there's always the chance that it'll brake down to be traded at skipped price-levels. I think one should watch out for PFE announcing Paxlovid being effective against the omicron variant, which could lead a lot of investors to switch to PFE. Today I want to see MRNA reclaiming the bullish channel at $377,xx and hold within this channel. From there on, it's more than a 30% ride to the top of the channel. But this stock has done crazy things like this in the past. Depending on how fast MRNA manages to reclaim the top, the price correlates with the last ATH at $494,xx. I think, if it manages to get back at the center of the channel, it will be rejected at the old resistance at $463,xx first, settle a bit and then trying to break the $500. My plan is to sell at $463 and then watch how things develop. But remember if, you're not in it by now, it maybe is bad timing to get in at this pricelevel. Risk is way to high, because of the gaps. That is why I marked this trading strategy as Neutral. Good luck in the markets! Again, this is not financial advice!
NASDAQ:MRNA
by robvanhoven
Are Pfizer, Merck and Moderna Still Worthy to Be in Portfolio?Pfizer is now outperforming Merck and Moderna stocks after announcing its anti-COVID pill despite its shares not being the best option for investments in the first half of this year. Pfizer stocks gained only 35% since the beginning of this year until mid-August. Moderna stocks were skyrocketed by 375% for the same period. So, undoubtedly Moderna was the favourite. However, when Merck announced the production of its COVID pills, the shares of vaccine producers spiraled into correction. But Merck was not the one to get its COVID pills into the market. Its shares peaked up to $91.40 and plunged with a gap after Pfizer announced its even more promising COVID treatment pills. The company said clinical trials showed that hospitalisation and deaths were reduced by 89% when the pill is taken within three days of the onset of symptoms.  So, this news from Pfizer came on November 5 and since then the technical picture for the above-mentioned three Big Pharma stocks changed dramatically. Pfizer shares are taking the lead while waving away all their August corrections and now they are close to the all-time highs at $51.86. If they are successful at breaking through this level, technical price acceleration may bring its stocks to $56.03 and $58.60 may be the next target. These levels could be a correction impulse to the decline from $51.86 to $40.94 per share. The nearest support level is at $47.70-48.80. As for Moderna stocks, the last quarter financial report hit them badly. Nevertheless, impulsive selloffs are now over as shares dipped to the important support level established in November 2020. So, now it is worth consider buying these shares. Corrections went into an ABC zigzag and shares are likely to return on the upside track. Initially, A and B waves were suggested to be equal, but now we see that the C wave is 161.8% of the A wave that gave us a decline to $225.85 per share. In my opinion Moderna shares have accomplished their correction and are close to the trend line of the last 12 month, and for that reason are an interesting investment. So, Moderna stocks may even be catching up to Pfizer. The nearest targets for Moderna stocks are within the area of $283-291 where EMA 21 moving average is located at the daily timeframe chart together with the resistance level formed by dips of July and October 2021. Moreover, at the $298 landmark, the resistance line of the downward trend that started on September 23 is located. If this zone would be broken the perspectives for Moderna stocks should be extended.Despite all these different technical pictures for these stocks, I would recommend holding all three stocks in your investment portfolio. Pfizer and Merck continue to compete in the COVID pills market while Moderna has a forward P/E ratio at 9, which highlights that the company is the cheapest among the Big Pharma biotech companies if compared with its peers sector performance.
NASDAQ:MRNALong
by scavoanastasiia
$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by BADQOMOCAWGOWLD
Hmmmm following the levels nicelyHaven’t opened up the chart for MRNA since it was around $400 these inverse fib levels are playing out perfectly though. Needs to claim $346.44 or hold $314.67 break below that and maybe catch support around $294. Below that it can get ugly again. So much uncertainty in the market right now. A lot of things(Covid plays) popped Friday based on the severity of the new variant. If the market decides that was unnecessary those plays could give a lot back.
NASDAQ:MRNA
by jmorg33